David Krause

Biography

Following a decade in the practice of internal medicine, Dr. Krause spent 12 years at SmithKline Beecham in vaccine development in the U.S., leading several worldwide clinical development groups. Upon the merger of SmithKline and Glaxo, he assumed new responsibilities, including North America Health Outcomes and Policy Development. Upon joining Vicuron in 2002 and prior to Vicuron's acquisition by Pfizer Pharmaceuticals, he assumed responsibilities for clinical development and NDA submissions including an antibiotic directed at infections caused by S. aureus, including methicillin-resistant variants. He attended Temple University School of Medicine and trained in internal medicine at the Medical College of Pennsylvania and Temple University Hospital. Dr. Krause is the author of numerous scientific publications and abstracts and is a Fellow of the American College of Physicians.

Research Interest

Following a decade in the practice of internal medicine, Dr. Krause spent 12 years at SmithKline Beecham in vaccine development in the U.S., leading several worldwide clinical development groups. Upon the merger of SmithKline and Glaxo, he assumed new responsibilities, including North America Health Outcomes and Policy Development. Upon joining Vicuron in 2002 and prior to Vicuron's acquisition by Pfizer Pharmaceuticals, he assumed responsibilities for clinical development and NDA submissions including an antibiotic directed at infections caused by S. aureus, including methicillin-resistant variants. He attended Temple University School of Medicine and trained in internal medicine at the Medical College of Pennsylvania and Temple University Hospital. Dr. Krause is the author of numerous scientific publications and abstracts and is a Fellow of the American College of Physicians.